Nasdaq

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary ...
Nasdaq

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

-- PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis -- -- Results to be presented today ...
Medindia

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG ...
Medindia

Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300

NEWARK, Calif., Sept. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National ...